(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure. (2) Consists of inventory impairment and costs associated with the settlement of ...
First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results